Cargando…

Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization

The immune responses to SARS-CoV-2 variants in COVID-19 cases are influenced by various factors including pre-existing immunity via vaccination and prior infection. Elucidating the drivers for upgrading neutralizing activity to SARS-CoV-2 in COVID-19 cases with pre-existing immunity will aid in impr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyamoto, Sho, Arashiro, Takeshi, Ueno, Akira, Kanno, Takayuki, Saito, Shinji, Katano, Harutaka, Iida, Shun, Ainai, Akira, Ozono, Seiya, Hemmi, Takuya, Hirata, Yuichiro, Moriyama, Saya, Kotaki, Ryutaro, Kinoshita, Hitomi, Yamada, Souichi, Shinkai, Masaharu, Fukushi, Shuetsu, Takahashi, Yoshimasa, Suzuki, Tadaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837220/ https://www.ncbi.nlm.nih.gov/pubmed/36687316 http://dx.doi.org/10.1016/j.isci.2023.105969

Ejemplares similares

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
por: Miyamoto, Sho, et al.
Publicado: (2022)

Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval
por: Miyamoto, Sho, et al.
Publicado: (2023)

Humoral immunity for durable control of SARS-CoV-2 and its variants
por: Kotaki, Ryutaro, et al.
Publicado: (2023)

SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine
por: Kotaki, Ryutaro, et al.
Publicado: (2022)

A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity
por: Moriyama, Yuki, et al.
Publicado: (2022)

Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain
por: Takano, Tomohiro, et al.
Publicado: (2023)

Assessment of SARS-CoV-2 infectivity of upper respiratory specimens from COVID-19 patients by virus isolation using VeroE6/TMPRSS2 cells
por: Yamada, Souichi, et al.
Publicado: (2021)

Pathology of Kaposi’s Sarcoma-Associated Herpesvirus Infection
por: Fukumoto, Hitomi, et al.
Publicado: (2011)

A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection
por: Iwata-Yoshikawa, Naoko, et al.
Publicado: (2022)

CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes
por: Onodera, Taishi, et al.
Publicado: (2023)

Impacts of allergic airway inflammation on lung pathology in a mouse model of influenza A virus infection
por: Kawaguchi, Akira, et al.
Publicado: (2017)

Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants
por: Seki, Yohei, et al.
Publicado: (2022)

Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant–Infected Vaccinees
por: Takahashi, Kenichiro, et al.
Publicado: (2022)

Structure-Guided Creation of an Anti-HA Stalk Antibody F11 Derivative That Neutralizes Both F11-Sensitive and -Resistant Influenza A(H1N1)pdm09 Viruses
por: Kotani, Osamu, et al.
Publicado: (2021)

Lung Pathology of Mutually Exclusive Co-infection with SARS-CoV-2 and Streptococcus pneumoniae
por: Tsukamoto, Tetsuya, et al.
Publicado: (2021)

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
por: Ohashi, Hirofumi, et al.
Publicado: (2022)

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants
por: Moriyama, Saya, et al.
Publicado: (2023)

Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters
por: Shiwa-Sudo, Nozomi, et al.
Publicado: (2023)

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants
por: Moriyama, Saya, et al.
Publicado: (2021)

Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology
por: Hemmi, Takuya, et al.
Publicado: (2022)

Acute Respiratory Infection in Human Dipeptidyl Peptidase 4-Transgenic Mice Infected with Middle East Respiratory Syndrome Coronavirus
por: Iwata-Yoshikawa, Naoko, et al.
Publicado: (2019)

Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults
por: Sonoyama, Takuhiro, et al.
Publicado: (2023)

Characterization of Quasispecies of Pandemic 2009 Influenza A Virus (A/H1N1/2009) by De Novo Sequencing Using a Next-Generation DNA Sequencer
por: Kuroda, Makoto, et al.
Publicado: (2010)

High expression of JC polyomavirus-encoded microRNAs in progressive multifocal leukoencephalopathy tissues and its repressive role in virus replication
por: Takahashi, Kenta, et al.
Publicado: (2020)

Coronavirus hunted in human pneumocytes and alveolar macrophages: a case report
por: Kataoka, Michiyo, et al.
Publicado: (2022)

Characterization of Persistent SARS-CoV Infection in Vero E6 Cells
por: Mizutani, Tetsuya, et al.
Publicado: (2006)

Association of human cytomegalovirus (HCMV) neutralizing antibodies with antibodies to the HCMV glycoprotein complexes
por: Shibamura, Miho, et al.
Publicado: (2020)

Phosphorylation of p38 MAPK and its downstream targets in SARS coronavirus-infected cells
por: Mizutani, Tetsuya, et al.
Publicado: (2004)

Importance of Akt signaling pathway for apoptosis in SARS-CoV-infected Vero E6 cells
por: Mizutani, Tetsuya, et al.
Publicado: (2004)

Regulation of p90RSK phosphorylation by SARS‐CoV infection in Vero E6 cells
por: Mizutani, Tetsuya, et al.
Publicado: (2006)

Enhancement of SARS-CoV Infection by Proteases
por: Matsuyama, Shutoku, et al.
Publicado: (2006)

cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue
por: Takaki, Hiromi, et al.
Publicado: (2017)

Insights into Pathology and Pathogenesis of Coronavirus Disease 2019 from a Histopathological and Immunological Perspective
por: Iida, Shun, et al.
Publicado: (2021)

Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
por: Shimojima, Masayuki, et al.
Publicado: (2015)

Coronavirus disease (COVID-19) associated delayed-onset fulminant myocarditis in patient with a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
por: Ishikura, Hiroyasu, et al.
Publicado: (2021)

JNK and PI3k/Akt signaling pathways are required for establishing persistent SARS-CoV infection in Vero E6 cells
por: Mizutani, Tetsuya, et al.
Publicado: (2005)

Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022
por: Kinoshita, Ryo, et al.
Publicado: (2023)

An Autopsy Report of a Case with Cerebral Infarction Complicated by Coronavirus Disease 2019 Infection
por: Goto, Ryoji, et al.
Publicado: (2022)

Varicella pneumonia in an immunocompetent, unvaccinated man: A case report
por: Okumura, Nobumasa, et al.
Publicado: (2021)

Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
por: Tani, Hideki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a1gdur7t3m7laolokb2aoneqjt